Inclusion Criteria:

          1. Newly diagnosed histologically proven locoregional OCSCC without evidence of distant
             metastases and a clinically determined T-stage of 2-4,

             OR

             Recurrent or persistent histologically proven locoregional OCSCC that was initially
             treated with surgery alone, and a clinically determined recurrent T-stage of 2-4.

             Note - OCSCC includes the subsites of oral tongue, floor of mouth, gingiva, retromolar
             trigone, and buccal mucosa.

             Note - To allow sufficient tumor tissue for the immunological analyses, patients with
             T-stage 1 OCSCC will be excluded

          2. Greater than or equal to 18 years of age

          3. ECOG performance status of 0 or 1

          4. Screening labs must meet the following criteria and must be obtained within 14 days
             prior to registration:

               -  WBC > 2,000/µL

               -  Absolute Neutrophil Count >1,500/µL

               -  Platelets > 100 X 103/µL

               -  Hemoglobin > 9.0 g/dL

               -  Serum creatinine < 1.5 X ULN or CrCl > 40mL/min (if using the Cockcroft-Gault
                  formula below):

             Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in
             mg/dL Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in
             mg/dL

               -  AST/ALT ≤ 3 x ULN

               -  Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have
                  total bilirubin < 3.0 mg/dL)

          5. Reproductive Status:

        WOCBP must use appropriate method(s) of contraception. WOCBP should use an adequate method
        to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo
        five half-lives) after the last dose of investigational drug.

        Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere
        to contraception with a failure rate of less than 1% per year for a period of 31 weeks
        after the last dose of investigational product.

        WOCBP is defined as any female who has experienced menarche and who has not undergone
        surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not
        postmenopausal. Menopause is defined clinically as 12 consecutive months of amenorrhea in a
        woman over 45.

        Women of childbearing potential must have a negative serum pregnancy test (minimum
        sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to registration Women
        who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile)
        and azoospermic men, are not required to use contraception.

        Exclusion Criteria:

          1. Prior immunotherapy or treatment with another anti PD 1 agent

          2. Prior chemotherapy including Cetuximab or radiation therapy

          3. Previous severe hypersensitivity reaction to another monoclonal antibody

          4. Women who are pregnant, lactating or expecting to conceive

          5. Men who are expecting to father children within the research period

          6. Known history of HIV or AIDS

          7. Positive test for HBV sAg or HCV antibody indicating acute or chronic infection

          8. Concomitant malignancies except cutaneous squamous cell carcinoma or basal cell
             carcinoma

          9. Unresectable primary tumor or regional disease; presence of distant metastases.

         10. History of pneumonitis or interstitial lung disease

         11. Active, known or suspected autoimmune disease. Note: Subjects are permitted to enroll
             if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to
             autoimmune condition only requiring hormone replacement, psoriasis not requiring
             systemic treatment, or conditions not expected to recur in the absence of an external
             trigger

         12. Presence of condition requiring systemic treatment with either corticosteroids (> 10
             mg daily prednisone or equivalents) or other immunosuppressive medications within 14
             days of study drug administration. Inhaled or topical steroids and adrenal replacement
             doses > 10 mg daily prednisone equivalents are permitted in the absence of active
             autoimmune disease